Sarcoma

Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas

By

In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.

Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma

By

The US FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

New Therapy Holds Promise for Patients With Ewing Sarcoma

By

Two new compounds suppress tumor growth in cell culture and mouse xenograft models of Ewing sarcoma, a rare pediatric cancer. These 2 compounds are similar to mithramycin, also known as picamycin, a drug no longer manufactured due to its toxicity.

Studies Demonstrate Clinical Advantages of Proton Therapy

Studies Demonstrate Clinical Advantages of Proton Therapy

By

The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.

Gene Signature May Predict Survival Outcomes for Some Children With Rhabdomyosarcoma

By

Among children with intermediate-risk rhabdomyosarcoma that is negative for a fusion gene, those who had a high score of the specific gene signature MG5 had poorer survival outcomes compared with those who had a low score of MG5.

FDA Approves Trabectedin for Metastatic or Unresectable Soft Tissue Sarcoma

FDA Approves Trabectedin for Metastatic or Unresectable Soft Tissue Sarcoma

By

The FDA has approved trabectedin (Yondelis) for treatment of unresectable or metastatic soft tissue sarcoma.

Trabectedin Confers Long-Term Efficacy in Soft Tissue Sarcoma

By

A large prospective postcommercialization study in patients with advanced STS in Europe confirmed the long-term anticancer activity of trabectedin (Yondelis) in different subtypes of sarcoma.

Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma

Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma

Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.

Survival from rare bone cancer remains low

By

Mesenchymal chondrosarcoma, which often affects young adults, is among the deadliest cancers.

Sarcoma patients' significant symptom burden negatively impacts quality of life

Sarcoma patients' significant symptom burden negatively impacts quality of life

Adult patients with sarcoma experience significant symptom burden, which has a strong negative impact on health-related quality of life.

Prolonged therapy with trabectedin recommended for soft-tissue sarcoma

By

Data from a phase 2 trial supports continuation of trabectedin for patients with advanced soft-tissue sarcoma (STS) who have not progressed after six courses of treatment.

Advanced image guidance more precisely targets sarcomas, reduces long-term side effects

Advanced image guidance more precisely targets sarcomas, reduces long-term side effects

Image-guided radiotherapy can effectively treat soft tissue sarcomas in the extremities.

PARP inhibitors plus chemotherapy may be effective for Ewing sarcoma

PARP inhibitors plus chemotherapy may be effective for Ewing sarcoma

A combination of experimental drugs caused Ewing sarcoma tumors to disappear in mice.

Ortho-oncology team achieves successful hip articulation by repurposing a shoulder surgical aid

By

A shoulder surgical aid, known as the Spider Limb Positioner, was adapted successfully to conduct a left hip disarticulation on a patient with melanoma.

Indications for pazopanib

Indications for pazopanib

By

Is pazopanib (Votrient) approved for the treatment of leiomyosarcoma?

Resistant sarcomas slowed by new therapeutic combination

By

A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.

Hemipelvectomy: Providing evidence-based nursing care

By

Meeting the challenges of the significant morbidity, functional impairment, and alterations in body image in patients undergoing this surgical resection.

Doxorubicin-ifosfamide combo improves progression-free survival in soft-tissue sarcoma

By

A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.

Prognostic factors of pazopanib in advanced soft tissue sarcomas

By

A new analysis confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. In addition, hemoglobin at baseline was found to be a new prognostic factor.

Potential therapeutic target identified for incurable, rare type of soft-tissue cancer

By

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, according to a new research report.

Carbon ion radiotherapy works for inoperable spinal sarcomas

By

Carbon ion radiotherapy (CIRT) appears to be safe and effective for the treatment of persons with unresectable spinal sarcoma, researchers have affirmed.

Sarcoma drug duo more effective than one or the other

Combining a Wee1 protein inhibitor with the chemotherapy agent gemcitabine reduced sarcoma tumor volume more than did either drug alone.

Expression, genomic patterns predict sarcoma progression

Expression, genomic patterns predict sarcoma progression

In synovial sarcoma, metastasis development is linked to chromosome complexity.

PET tracer identifies which liposarcoma tumors may respond to chemotherapy

By

Researchers have identified a group of liposarcoma tumors that can be imaged by positron emission tomography scans using a tracer substance known as FAC.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Regorafenib prolongs survival in face of GI cancers

Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.

Possible new treatment for Ewing sarcoma

By

Discovery of a new drug with high potential to treat Ewing sarcoma and of the previously unknown mechanism behind the disease came hand-in-hand.

Well-known antifungal drug shows promise against cancer

Thiabendazole, an antifungal drug in clinical use for 40 years, inhibits angiogenesis, slows tumor growth, and reduces vascular density of tumors.

Ridding cells of EYA3 boosts chemotherapy response in Ewing sarcoma

Scientists have identified a protein that makes some children and teenagers afflicted with Ewing sarcoma more resistant to chemotherapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs